The activation of the interferon pathway in depression is also consistent with studies reporting an increased prevalence of clinically relevant depression in patients receiving IFN-I therapies (IFN-α for hepatitis C or IFN-β for multiple sclerosis) [29, 48]. This evidence concerns the gene IFNB1 and depressive symptom measurement.